Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening.
All News
Dr. John Cush
Tweet
Study of 162axSpA pts found that 46.6% reported abnormal sleep behavior, worse in Female patients vs males (P <.001). Such pts were more likely to have depression (P = .015) and worse health-related QoL (HRQOL) (P = .015) https://t.co/a1OoUTPKiV https://t.co/gkjkkdljOh
Dr. John Cush
Tweet
Report of 54 nonradiographic axial SpA pts w/ recurrent fever. Fever preceded SpA in all; age @ axSpA Dx 39.9 yrs, w/ Dx delay 9.3 yrs. Fevers 38-42°C, arthralgia 61%, myalgia 44%, arthritis 41%, GI 25%, Rash 22%. Best Rx to TNFi > IL1i, colchicine, DMARD https://t.co/muSYhZFXku https://t.co/1lUPCMyuCX
Dr. John Cush
Tweet
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/kmjo3HYg4K https://t.co/PINZryXQBP
Dr. John Cush
Tweet
Watch: Zoster Management and Vaccination
Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy.
https://t.co/eOhXzw3Epy https://t.co/h3NoDggg5x
Dr. John Cush
Tweet
Watch: SpA and Interstitial Lung Disease
Dr. Eric Ruderman discusses abstract OP0006 presented at EULAR 2023 in Milan, Italy.
https://t.co/wsR3gv1jSr https://t.co/ULYbJeoFHi
Dr. Antoni Chan
Tweet
The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023 @RheumNow https://t.co/5byn0kBEIQ
Dr. Antoni Chan
Tweet
Dual IL-17A/F inhibition with Bimekizumab reduced MRI inflammatory change in the SIJ and spine in AxSpA, and increasing proportion achieving MRI remission at Wk52, Abst#POS0246 #EULAR2023 @RheumNow https://t.co/w4VkkUklGl
Dr. Antoni Chan
Tweet
The International Map of AxSpA (IMAS) of >5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023 @RheumNow https://t.co/wB9Jtbgvy7
Dr. Antoni Chan
Tweet
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan
Tweet
In an early SpA (DESIR) cohort, the occurrence of a first pregnancy did not seem to increase the number of imaging abnormalities of the SIJ. Overall no significant changes in radiographic and MRI imaging abnormalities of the SIJ, Molto A, Abst#POS0303, #EULAR2023 @RheumNow
Dr. Antoni Chan
Tweet
The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023 @RheumNow https://t.co/i5GZMcJwyO
Md Yuzaiful Md Yusof
Tweet
#EULAR2023 Clinical Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs.
OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis @RheumNow https://t.co/GoUPfpwTLq
Dr. John Cush
Tweet
Tune it at 1pm EST for RheumNow's daily #EULAR23 recaps. You can find us live on Twitter, YouTube and LinkedIn. https://t.co/t531csjXo8
Aurelie Najm
Tweet
We need to assess CV risk in IA but how?
Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO
Bummer: these 3 prediction tools are less accurate in IA but also OA.
We need a dedicated tool.
@Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
David Liew
Tweet
Just a reminder: nr-axSpA isn’t destined to become r-axSpA/AS. Life is more complicated than that.
Between the natural history and TNFi, very small conversion rate post-10y. Of course, whatever the x-rays, it can still disable though
DESIR cohort POS0675 #EULAR2023 @RheumNow https://t.co/29HeJXpK2S
Md Yuzaiful Md Yusof
Tweet
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed:
- 1 in 10 people had AID in the last 20yrs
- socioeconomic, seasonal & regional disparities cd influence pathogenesis
- CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Dr. John Cush
Tweet
Chinese study 43 axSpA pts Rx w/ Secukinumab-37 pts had HBV & 16% (6) reactivated HBV after mean 9 mos of SEC (5 w/ chronic HBV, 1 occult HBV). 2 pts chronic HBV reactivated despite anti-HBV prophylaxis. 6 axSpA w/ LTBI - none had TB on SEC https://t.co/o4gA9mcD2R https://t.co/XKwp2z9U3K
David Liew
Tweet
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
Dr. Antoni Chan
Tweet
AxSpA can be unequivocally diagnosed in the first 2 years of onset of chronic back pain with 30% definite with HLA-B27+ and imaging being the key SpA features from the SPACE cohort by
Mary Lucy Marques, Abst #OP0005 @RheumNow https://t.co/m5umD00hDf
